BioNTech SE ADR [BNTX] stock is trading at $120.76, up 6.74%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BNTX shares have gain 18.54% over the last week, with a monthly amount glided 9.30%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on November 19, 2024, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $125 from $110. Previously, Berenberg started tracking the stock with Buy rating on November 19, 2024, and set its price target to $130. On November 08, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $137 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $145 on September 24, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $150 on September 17, 2024. JP Morgan upgraded its rating to Neutral for this stock on September 16, 2024, and upped its price target to $125. In a note dated August 07, 2024, Deutsche Bank upgraded an Buy rating on this stock but restated the target price of $95.
BioNTech SE ADR [BNTX] stock has fluctuated between $76.53 and $131.49 over the past year. Currently, Wall Street analysts expect the stock to reach $165.07 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $120.76 at the most recent close of the market. An investor can expect a potential return of 36.69% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
BioNTech SE ADR [NASDAQ:BNTX] reported sales of 3.30B for the trailing twelve months, which represents a growth of 40.41%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 115.76 points at the first support level, and at 110.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 123.43, and for the 2nd resistance point, it is at 126.11.
Ratios To Look Out For
For context, BioNTech SE ADR’s Current Ratio is 7.33. In addition, the Quick Ratio stands at 7.21 and the Cash Ratio stands at 3.82. Considering the valuation of this stock, the price to sales ratio is 8.77, the price to book ratio is 1.36.
Transactions by insiders
Recent insider trading involved ATHOS KG, 10% Owner, that happened on Nov 25 ’24 when 75000.0 shares were purchased. Director, Jeggle Helmut Wolfgang completed a deal on Nov 15 ’24 to buy 0.15 million shares. Meanwhile, Officer Tureci Ozlem bought 0.56 million shares on Nov 12 ’24.
